top of page

Burdensome step therapy requirements could delay care for cancer patients: analysis

Restrictive health plan policies are increasingly relying on step therapy for cancer drugs, recent analysis from consulting firm Avalere shows.

A white paper (PDF) released by the American Cancer Society Cancer Action Network (ACSCAN) showed step therapy is often embedded within prior authorization requirements, at times unknowingly at first glance to consumers.


bottom of page